{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-001894","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.985035+00:00","generated_at":"2026-06-07T02:44:36.961774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ImmuCell reports Q4 2023 product sales of $5.1M, up 30% YoY; backlog grows to $9.4M","bullets":["Q4 2023 sales $5.1M vs $3.9M in Q4 2022 (+30.3%); full-year 2023 sales $17.5M vs $18.6M (-5.9%).","Backlog $9.4M as of Dec 31, 2023, up from $2.5M a year ago, driven by production disruptions from contamination events.","Production output improved in Nov/Dec 2023, annualizing ~$26.8M; company targeting >$6M quarterly production.","FDA response on Re-Tain CMC Technical Section expected by May 2024.","Conference call to discuss full results on Feb 22, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-001894","json":"https://secwatch.observer/filing/0001213900-24-001894.json","markdown":"https://secwatch.observer/filing/0001213900-24-001894.md","text":"https://secwatch.observer/filing/0001213900-24-001894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/0001213900-24-001894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/ea191339-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:44:36.961774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08f88d473612fac30641e5ef68e7b0d8d90e6413","claim":"IMMUCELL CORP /DE/ reported preliminary financial results for the fourth quarter of 2023, which ended December 31, 2023.","evidence_excerpt":"On January 8, 2024 ImmuCell Corporation (the \"Company\") issued a press release announcing its unaudited product sales for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/0001213900-24-001894-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023, which ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"40c1a87ec38c91f91c8c942b5349b180cdad5025","claim":"IMMUCELL CORP /DE/ reported preliminary financial results for the year ended December 31, 2023.","evidence_excerpt":"On January 8, 2024 ImmuCell Corporation (the \"Company\") issued a press release announcing its unaudited product sales for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/0001213900-24-001894-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}